Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Century Therapeutics (IPSC – Research Report), retaining the price target of $2.00.
Mitchell Kapoor has given his Buy rating due to a combination of factors related to Century Therapeutics’ advancements and strategic pivots. The company has showcased its preclinical pipeline and introduced its latest AlloEvasion 5.0 technology, which features significant improvements over its predecessor. These advancements include the retention of key immune evasion edits and the addition of new mechanisms to enhance the therapeutic potential of their cell therapies.
Furthermore, Century Therapeutics is preparing its CNTY-301 for IND-enabling studies, indicating progress in its pipeline. Although the company has shifted its focus from oncology to autoimmune diseases for CNTY-101, Kapoor sees potential in this pivot, especially with the initiation of the CALiPSO-1 trial. Despite the need for more clinical data to confirm the efficacy of their approach, the promising preclinical data and strategic developments support Kapoor’s Buy rating.
Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Cartesian Therapeutics, and Halozyme. According to TipRanks, Kapoor has an average return of -25.5% and a 25.40% success rate on recommended stocks.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $2.00 price target.